Literature DB >> 16493607

Recognition and management of methemoglobinemia and hemolysis in a G6PD-deficient patient on experimental anticancer drug Triapine.

Lynda M Foltz1, Bakul I Dalal, Louis D Wadsworth, Raewyn Broady, Kim Chi, Elizabeth Eisenhauer, Ken Kobayashi, Christian Kollmannsburger.   

Abstract

We report occurrence of severe methemoglobinemia in a patient on novel experimental anti-cancer drug, Triapine. Treatment with methylene blue led to massive hemolysis due to concomitant G6PD deficiency. We recommend that G6PD screening be done in high-risk populations prior to commencement of Triapine therapy.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16493607     DOI： 10.1002/ajh.20547

Source DB:  PubMed          Journal:  Am J Hematol        ISSN： 0361-8609            Impact factor:   10.047


  13 in total

1.  Phase II trial of the ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehydethiosemicarbazone plus gemcitabine in patients with advanced biliary tract cancer.

Authors:  Allyson J Ocean; Paul Christos; Joseph A Sparano; Dan Matulich; Andreas Kaubish; Abby Siegel; Max Sung; Maureen M Ward; Nancy Hamel; Igor Espinoza-Delgado; Yun Yen; Maureen E Lane
Journal:  Cancer Chemother Pharmacol       Date:  2010-10-28       Impact factor: 3.333

2.  Improvement in Hemodynamics After Methylene Blue Administration in Drug-Induced Vasodilatory Shock: A Case Report.

Authors:  JoAn R Laes; David M Williams; Jon B Cole
Journal:  J Med Toxicol       Date:  2015-12

Review 3.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

4.  Population pharmacokinetics of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (Triapine®) in cancer patients.

Authors:  Jill Kolesar; Richard C Brundage; Marcia Pomplun; Dona Alberti; Kyle Holen; Anne Traynor; Percy Ivy; George Wilding
Journal:  Cancer Chemother Pharmacol       Date:  2010-05-04       Impact factor: 3.333

5.  Unsuspected glucose-6-phosphate dehydrogenase deficiency presenting as symptomatic methemoglobinemia with severe hemolysis after fava bean ingestion in a 6-year-old boy.

Authors:  Marie-Hélène Odièvre; Névéna Danékova; Bettina Mesples; Myriam Chemouny; Nathalie Couque; Nathalie Parez; Rolande Ducrocq; Jacques Elion
Journal:  Int J Hematol       Date:  2011-04-12       Impact factor: 2.490

Review 6.  Methylene blue-induced methemoglobinemia during cardiopulmonary bypass? A case report and literature review.

Authors:  Craig M McRobb; David W Holt
Journal:  J Extra Corpor Technol       Date:  2008-09

7.  A phase 2 consortium (P2C) trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP) for advanced adenocarcinoma of the pancreas.

Authors:  Steven Attia; Jill Kolesar; Michelle R Mahoney; Henry C Pitot; Daniel Laheru; James Heun; Wei Huang; Jens Eickhoff; Charles Erlichman; Kyle D Holen
Journal:  Invest New Drugs       Date:  2008-02-16       Impact factor: 3.850

8.  A multicenter phase II trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) and gemcitabine in advanced non-small-cell lung cancer with pharmacokinetic evaluation using peripheral blood mononuclear cells.

Authors:  Brigette Ma; Boon Cher Goh; Eng Huat Tan; Kwok Chi Lam; Ross Soo; Swan Swan Leong; Ling Zhi Wang; Frankie Mo; Anthony T C Chan; Benny Zee; Tony Mok
Journal:  Invest New Drugs       Date:  2007-09-12       Impact factor: 3.850

9.  Phase II study of Triapine in patients with metastatic renal cell carcinoma: a trial of the National Cancer Institute of Canada Clinical Trials Group (NCIC IND.161).

Authors:  Jennifer J Knox; Sebastien J Hotte; Christian Kollmannsberger; Eric Winquist; Bryn Fisher; Elizabeth A Eisenhauer
Journal:  Invest New Drugs       Date:  2007-03-28       Impact factor: 3.850

10.  PharmGKB summary: methylene blue pathway.

Authors:  Ellen M McDonagh; José M Bautista; Ilan Youngster; Russ B Altman; Teri E Klein
Journal:  Pharmacogenet Genomics       Date:  2013-09       Impact factor: 2.089
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.